英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home - Mesoblast Ltd
    Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care
  • Mesoblast - Wikipedia
    Mesoblast Limited is an Australian regenerative medicine company It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain The company is led by Silviu Itescu, who founded the company in 2004 [1]
  • Mesoblast Limited (MESO) - Yahoo Finance
    Find the latest Mesoblast Limited (MESO) stock quote, history, news and other vital information to help you with your stock trading and investing
  • Mesoblast finally pushes GvHD cell therapy over finish line
    Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children undergoing HSCT
  • After two rejections, FDA approves Mesoblasts GVHD cell therapy
    After two rejections from the FDA, Mesoblast has finally gained approval for its first drug, Ryoncil, a cell therapy for graft versus host disease
  • FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
    Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients aged a minimum of two months and up to adolescents and teenagers
  • Overview - Mesoblast Ltd
    Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions
  • Mesoblast Gives Positive Update About Potential FDA Application . . . - MSN
    Mesoblast (MESO) said on Thursday it is awaiting the final minutes from the U S Food and Drug Administration (FDA) to provide timelines for potential filing for its late-stage product candidate
  • Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway . . .
    Mesoblast Limited NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update
  • In landmark, FDA approves first MSC therapy, Mesoblasts Ryoncil for . . .
    In a landmark decision, today the FDA approved Ryoncil from Mesoblast for GvHD This is the first time the FDA has approved a mescenchymal stromal stem cell or MSC therapy of any kind There have been many ups and downs for Mesoblast toward this approval of Ryoncil or remestemcel-L, an allogeneic marrow MSC product





中文字典-英文字典  2005-2009